# ResMed: how the business works

> For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

ResMed Inc. · NYSE: RMD · Sector: Health Care

Updated for Q1 FY2027 · checked Nov 20, 2026

This is the plain-text version of https://cityfort.co/stocks/resmed. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, ResMed: how the business works", with the page URL.

## The 30-second summary

ResMed makes sleep apnea machines, masks and home ventilators, and sells software to home care providers, with net revenue of $5.65 billion in FY2026. Of every $100 that came in that year, $26.8 was left as net income, and US customers made up 63.0% of revenue (Cityfort calculation from the FY2026 10-K). Its FY2026 10-K says GLP-1 weight-loss drugs could reduce the severity of sleep apnea, while device revenue grew 9% that year.

## 5 points

- **What it sells:** ResMed sells sleep apnea machines, masks, home ventilators and care software, with net revenue of $5.65 billion in FY2026: devices $2.89 billion and masks and other products $2.09 billion. [S2]
- **Who pays it:** US customers, mainly equipment suppliers, health systems and sleep clinics that bill insurers, made up 63.0% of FY2026 revenue and customers in the rest of the world 37.0% (Cityfort calculation from the FY2026 10-K). [S2]
- **What it keeps from $100:** Of every $100 that came in during FY2026, ResMed kept $26.8 as net income, after $41.9 million of Astral ventilator safety costs; other income added only $32.7 million, and the GAAP operating margin was 33.4%. [S2, S20]
- **Where the operating profit comes from:** Sleep and Breathing Health brought in 88% of FY2026 revenue and earned $44.3 of segment profit per $100 of its revenue before corporate costs (Cityfort calculation from the FY2026 10-K). [S2]
- **The one thing to watch:** ResMed's FY2026 10-K says GLP-1 weight-loss drugs could reduce the severity of sleep apnea, while its device revenue grew 9% in FY2026 and 5.9% in Q1 FY2027. [S2, S1]

## What does ResMed sell?

ResMed makes the bedside machines and masks that people with sleep apnea wear at night. In sleep apnea, breathing stops and starts during sleep. A CPAP machine blows air through a mask to keep the airway open. ResMed also sells software that home care providers use to run their work.

- **Sleep apnea machines:** CPAP, APAP and bilevel devices such as AirSense and AirCurve push air through a mask overnight. Cloud-connected models link to AirView, which lets clinicians monitor patients remotely and change device settings. [S2]
- **Masks and accessories:** Masks, tubing and other parts sold with the machines. Masks, diagnostics and accessories were about 37% of revenue in FY2026, the 10-K says. [S2]
- **Ventilators and breathing devices:** Life-support and home ventilators such as Astral, and high-flow devices for lung conditions such as COPD. [S2]
- **Diagnostics and new therapies:** Home sleep tests; VirtuOx, a testing business bought in 2025; and Noctrix Health, bought in June 2026, which sells a wearable for restless legs syndrome. [S2, S15]
- **Residential Care Software:** Software for care outside hospitals: Brightree for US medical equipment suppliers and MEDIFOX DAN for care providers in Germany. MatrixCare was sold on Sep 1, 2026. [S2, S1]
- **AirView and myAir apps:** AirView lets clinicians check patients remotely; myAir lets patients track their own therapy. More than 35 million patients use cloud-connected devices on AirView. [S2]

## Who pays ResMed?

- **US equipment suppliers, health systems and sleep clinics:** They buy the machines and masks, set them up for patients and bill Medicare, Medicaid or private insurers. Customers in the United States made up 63.0% of FY2026 revenue (Cityfort calculation from the FY2026 10-K). [S2]
- **Distributors and direct customers outside the US:** Outside the US, ResMed sells through its own sales staff and independent distributors. The rest of the world made up 37.0% of FY2026 revenue (Cityfort calculation from the FY2026 10-K). [S2]
- **Software customers (12.0% of revenue):** Equipment suppliers, pharmacies and care providers pay for Brightree and MEDIFOX DAN software. The software segment brought in $675.8 million in FY2026. [S2]
- **Insurers and government payors (indirect):** Medicare, Medicaid and private health plans pay the suppliers, not ResMed. Their coverage rules decide which patients get a device. [S2]
- **Customer concentration:** largest customer 11.0% of revenue. No customer reached 10% of revenue in FY2024, FY2025 or FY2026. In Q1 FY2027 one unnamed customer was 11% of total revenue, across both segments, the Q1 FY2027 10-Q says. [S2, S1]

## Where the money went (FY2026)

1. Customers paid $5.65 billion for machines, masks and software in FY2026.
2. Making the products cost $2.20 billion. That included $41.9 million for an Astral ventilator field safety notification.
3. Selling and running the company cost $1.12 billion, and research took $378 million.
4. Interest and other income added $33 million, and income taxes took $396 million.
5. $1.52 billion was left as net income.

Sources: S2.

## Key numbers by year (US$ million)

Financials: consolidated, US$ million. Fiscal years are the company's own: Fiscal year ends June 30 (FY2026 = Jul 1, 2025 to Jun 30, 2026). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (US$ per share, diluted) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY2022 | 3,578.1 | 1,159.9 | 32.4% | 779.4 | 21.8% | 5.3 | 351.1 | 134.8 | 216.3 | S14 |
| FY2023 | 4,223 | 1,297 | 30.7% | 897.6 | 21.3% | 6.09 | 693.3 | 119.7 | 573.6 | S13 |
| FY2024 | 4,685.3 | 1,496.8 | 31.9% | 1,021 | 21.8% | 6.92 | 1,401.3 | 99.5 | 1,301.8 | S10 |
| FY2025 | 5,146.3 | 1,883.8 | 36.6% | 1,400.7 | 27.2% | 9.51 | 1,751.6 | 89.9 | 1,661.7 | S6 |
| FY2026 | 5,653.4 | 2,088.1 | 36.9% | 1,523.3 | 26.9% | 10.43 | 1,805.8 | 156.3 | 1,649.5 | S2 |

- EBITDA here = operating income plus depreciation and amortization (from the cash flow statement).
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of Sep 30, 2026, US$ million)

ResMed had $601 million more cash than debt at Sep 30, 2026 (Cityfort calculation from the Q1 FY2027 10-Q). [S1, S2, S19]

| Item | Value |
| --- | --- |
| Total debt | 409.6 |
| Cash and investments | 1,010.7 |
| Net debt (debt minus cash) | −601.1 |
| Net worth (shareholders' money) | 5,947.7 |
| Debt to equity (times) | 0.07 |

- Net cash is $1.01 billion of cash minus $409.6 million of debt at Sep 30, 2026 (Cityfort calculation from the Q1 FY2027 10-Q). At Jun 30, 2026 it was $809.9 million (Cityfort calculation from the FY2026 10-K).
- ResMed repaid its $250 million 3.24% senior notes on Jul 10, 2026. Its $250 million 3.45% senior notes are due Jul 10, 2029.
- A $1.5 billion revolving credit agreement and a term credit agreement both end on Jun 29, 2027, the FY2026 10-K says.
- Cash fell from $1.47 billion at Jun 30, 2026 to $1.01 billion at Sep 30, 2026. In that quarter ResMed spent $936.4 million on buybacks, repaid $250 million of debt and received $450.8 million from the MatrixCare sale.
- Debt here is borrowings only; lease liabilities are not included.
- Goodwill was $2.91 billion at Jun 30, 2026, or 32.5% of total assets of $8.97 billion (Cityfort calculation from the FY2026 10-K).

## Who owns ResMed? (as of Sep 22, 2026)

No single holder controls ResMed. Each share has one vote, and the 14 directors and executive officers together held 0.58% at Sep 22, 2026. [S15, S1]

- Officers and directors (as a group), shares: 0.58%

| Class | Shares (millions) | Votes per share | % of shares | % of votes | Traded | Sources |
| --- | --- | --- | --- | --- | --- | --- |
| Common stock (140,639,154 shares at Sep 30, 2026 (Q1 FY2027 10-Q), down from 144,239,563 at Jun 30, 2026. The stock also trades on the ASX as CHESS Depositary Instruments; ten equal one share.) | 140.64 | 1 | — | — | Yes | S1, S2 |

Holders of 5% or more (each row shows the date of its own filing):

| Holder | Shares | Votes | As of | Note | Sources |
| --- | --- | --- | --- | --- | --- |
| BlackRock, Inc. | 9.09% | — | Jan 25, 2024 | 12,783,715 shares, as listed in the 2026 proxy from a Schedule 13G/A filed Jan 25, 2024. That filing is old, so the current holding may differ. | S15 |
| Vanguard Capital Management LLC | 8.51% | — | Apr 29, 2026 | 11,961,706 shares, as listed in the 2026 proxy from a Schedule 13G filed Apr 29, 2026. | S15 |
| AustralianSuper Pty Ltd | 5.88% | — | Aug 7, 2026 | 8,276,381 shares, as listed in the 2026 proxy from a Schedule 13G filed Aug 7, 2026. | S15 |
| Vanguard Portfolio Management LLC | 5.61% | — | Apr 29, 2026 | 7,886,489 shares, from a Schedule 13G filed Apr 29, 2026. The proxy lists the two Vanguard entities separately. | S15 |

## What could go wrong

### Weight-loss drugs could reduce sleep apnea

The FY2026 10-K says GLP-1 weight-loss drugs may lower obesity and could reduce the severity of sleep apnea if weight loss is maintained. That could cut demand for ResMed's machines over time. [S2]

What to watch: Device revenue growth in each quarterly release (+9% in FY2026).

### Philips's return to the US market

Philips, a main rival, operates in the US under a consent decree after its product recall. ResMed says it cannot predict the timing or effect of a substantial Philips return. [S2]

What to watch: Americas device growth and any change to the Philips consent decree.

### US insurance and Medicare payment rules

US suppliers depend on Medicare, Medicaid and private insurers to pay for devices. Medicare is preparing a 2028 nationwide competitive bidding round, and a 2022 VA proposal would cut sleep apnea disability ratings. [S2]

What to watch: Which product categories Medicare places in the Round 2028 competitive bidding program.

### Single-source parts, magnets and tariffs

Some components come from single-source suppliers. The 10-K warns that China's rare-earth export controls and tariffs could raise magnet costs or delay deliveries. [S2, S19]

What to watch: GAAP gross margin in each release (61.5% in Q1 FY2027).

### One customer at 11% of revenue

In Q1 FY2027 one unnamed customer was 11% of total revenue, the 10-Q says. No customer reached 10% in the same quarter a year earlier. [S1]

What to watch: Whether later 10-Qs and the 10-K keep reporting a customer above 10%.

### Patent lawsuits

Cleveland Medical Devices has filed suits since 2022 alleging that connected devices and AirView infringe its patents. Fractus filed a suit in October 2025 alleging AirSense and AirCurve devices infringe its antenna patents. ResMed says it cannot estimate any loss. [S2, S1]

What to watch: Patent Office decisions and court rulings in the Cleveland Medical and Fractus cases.

### Product safety actions

A field safety notification is a notice to customers about a problem with a device, and it adds costs. An Astral ventilator notification cost $41.9 million in Q4 FY2026, booked in cost of sales. [S20]

What to watch: Field safety costs in the non-GAAP reconciliation of each release.

### Higher tax rate

The Pillar Two global minimum tax raised ResMed's tax rate, and Singapore tax holidays expire in whole or part through Jun 30, 2030. The effective rate was 22.4% in Q1 FY2027, against 22.0% a year earlier. [S1]

What to watch: The effective tax rate in each 10-Q.

## What to watch

Next: Q2 FY2027 results, Date not announced yet.

- **Device growth and weight-loss drugs:** Device revenue grew 9% in FY2026 and 5.9% in Q1 FY2027. The 10-K names GLP-1 drugs as a possible drag on demand.
- **Medicare's Round 2028 competitive bidding:** Watch which product categories Medicare places in the nationwide bidding round. US customers made up 63.0% of FY2026 revenue (Cityfort calculation from the FY2026 10-K).
- **Share buyback settlement:** The $450 million accelerated share repurchase with Citibank settles by Dec 29, 2026. ResMed spent $936.4 million on buybacks in Q1 FY2027.
- **Results against the company's guidance:** On Oct 29, 2026, management guided to FY2027 reported revenue of $5.75 billion to $5.85 billion. Q1 FY2027 revenue was $1.41 billion.

## Sources

- S1: Form 10-Q for Q1 FY2027. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000094381926000089/0000943819-26-000089-index.htm (published Oct 30, 2026)
- S2: Form 10-K for FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000094381926000047/0000943819-26-000047-index.htm (published Aug 13, 2026)
- S3: Form 10-Q for Q3 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000094381926000025/0000943819-26-000025-index.htm (published May 1, 2026)
- S4: Form 10-Q for Q2 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000094381926000007/0000943819-26-000007-index.htm (published Jan 30, 2026)
- S5: Form 10-Q for Q1 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000094381925000090/0000943819-25-000090-index.htm (published Oct 31, 2025)
- S6: Form 10-K for FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000094381925000035/0000943819-25-000035-index.htm (published Aug 8, 2025)
- S7: Form 10-Q for Q3 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000094381925000008/0000943819-25-000008-index.htm (published Apr 24, 2025)
- S8: Form 10-Q for Q2 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000094381925000004/0000943819-25-000004-index.htm (published Jan 31, 2025)
- S9: Form 10-Q for Q1 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000094381924000027/0000943819-24-000027-index.htm (published Oct 25, 2024)
- S10: Form 10-K for FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000094381924000013/0000943819-24-000013-index.htm (published Aug 9, 2024)
- S11: Form 10-Q for Q3 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000094381924000008/0000943819-24-000008-index.htm (published Apr 26, 2024)
- S12: Form 10-Q for Q2 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000094381924000003/0000943819-24-000003-index.htm (published Jan 25, 2024)
- S13: Form 10-K for FY2023. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/0000943819-23-000011-index.htm (published Aug 11, 2023)
- S14: Form 10-K for FY2022. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000094381922000010/0000943819-22-000010-index.htm (published Aug 12, 2022)
- S15: 2026 proxy statement (DEF 14A). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000094381926000080/rmd-20261001.htm (published Oct 1, 2026)
- S16: 8-K filed Aug 17, 2026 (auditor change from KPMG to PwC; director changes). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000119312626354154/d292919d8k.htm (published Aug 17, 2026)
- S17: 8-K filed Sep 1, 2026 ($450 million accelerated share repurchase). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000119312626378487/d530283d8k.htm (published Sep 1, 2026)
- S18: 8-K filed Jul 7, 2026, Ex. 99.1 (MatrixCare sale to Frazier Healthcare Partners). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000119312626297658/d88958dex991.htm (published Jul 7, 2026)
- S19: Q1 FY2027 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000119312626437783/d170451dex991.htm (published Oct 29, 2026)
- S20: Q4 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000119312626337962/d158732dex991.htm (published Aug 6, 2026)
- S21: Q3 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000119312626197192/d146862dex991.htm (published Apr 30, 2026)
- S22: Q2 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000119312626029326/d80310dex991.htm (published Jan 29, 2026)
- S23: Q1 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000119312625258519/d92301dex991.htm (published Oct 30, 2025)
- S24: Q4 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/943819/000119312625170512/d926247dex991.htm (published Jul 31, 2025)
